NCT02571036 2023-12-13A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesDeciphera Pharmaceuticals, LLCPhase 1 Completed282 enrolled
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled